Blog Big Molecule Watch August 30, 2017

SAMSUNG BIOEPIS FILES FOR JOINDER WITH HOSPIRA PETITIONS AGAINST GENENTECH PATENTS

Samsung Bioepis has filed three petitions for IPR challenging Genentech patents related to the use of Herceptin® (trastuzumab): IPR2017-01958, challenging U.S. Patent 6,627,196; IPR2017-01959 challenging U.S. Patent 7,371,379; and IPR2017-01960 challenging U.S. Patent 7,892,549.  Samsung Bioepis concurrently filed motions for joinder with Hospira’s petitions challenging the same patents (IPR2017-00804, IPR2017-00805, and IPR2017-00737), and which were instituted by the Board.

 

The post SAMSUNG BIOEPIS FILES FOR JOINDER WITH HOSPIRA PETITIONS AGAINST GENENTECH PATENTS appeared first on Goodwin Procter BioSimilars Blog.